Items Tagged ‘Chronic Lymphocytic Leukemia’

June 25, 2018

FDA Approves Venetoclax for Chronic and Small Lymphocytic Leukemia/Lymphoma With or Without 17 p Deletion,

By

The Food and Drug Administration granted regular approval to Venclexta (venetoclax) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Approval was based on a multicenter, open-label clinical trial of venclexta with rituximab (VEN+R) versus bendamustine with rituximab (B+R) […]

View full entry

Tags: Chronic Lymphocytic Leukemia, Leukemia, News


March 22, 2018

Venclexta Significantly Reduces Cancer Progression in Chronic Lymphocytic Leukemia

By

CancerConnect News: Venclexta (venetoclax) plus Rituxan (rituximab) significantly reduces the risk of cancer progression or death at two years, compared with Treanda (bendustamine) plus Rituxan in the treatment of chronic lymphocytic leukemia that has recurred following prior therapies. These results were recently presented at the 59th annual meeting of the American Society of Hematology (ASH). […]

View full entry

Tags: Chronic Lymphocytic Leukemia, cll Venetoclax, Leukemia, News, rituxan, rituximab


September 11, 2017

Duvelisib; Promising New Treatment Option for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

By

Results of the Phase 3 DUO study evaluating duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) have been reported and appear very promising.  Although the treatment of CLL/SLL has advanced in recent years, there remains a substantial unmet need with many patients progressing or relapsing following the available therapies […]

View full entry

Tags: Azerra, Chronic Lymphocytic Leukemia, Duvelisib, News, non-hodgkin lymphoma, Non-Hodgkin's Lymphoma, ofatumumab, Small Lymphocytic Lymphoma